Cite
Voortman J, Pham TV, Knol JC, et al. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci. 2009;7:34doi: 10.1186/1477-5956-7-34.
Voortman, J., Pham, T. V., Knol, J. C., Giaccone, G., & Jimenez, C. R. (2009). Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome science, 734. https://doi.org/10.1186/1477-5956-7-34
Voortman, Johannes, et al. "Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling." Proteome science vol. 7 (2009): 34. doi: https://doi.org/10.1186/1477-5956-7-34
Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci. 2009 Sep 03;7:34. doi: 10.1186/1477-5956-7-34. PMID: 19728888; PMCID: PMC2746186.
Copy
Download .nbib